Adverse events (number of events) ( · children aged from 29 days to 12 years with pneumonia
Chest physiotherapy showed no clear difference in adverse events (number of events) ( compared with no chest physiotherapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Child adverse events ‐ not measured · children and their families
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Any adverse events · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes adverse effects: Any adverse events compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: haematuria 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: leukopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: leukopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Serious adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
Intervention not reported
Investigator‐defined adverse events · adults without prevalent cardiovascular disease (primary cardiovascular disease prevention)
The intervention showed no clear difference in investigator‐defined adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (flap‐complications) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Serious adverse events (proportion) · people with acute pancreatitis
It is very uncertain whether the intervention changes serious adverse events (proportion) (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found